Journal
Clinical Cancer Research
Publication Date
5-15-2025
Volume
31
Issue
10
First Page
1847
Last Page
1855
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-24-2618
Rights and Permissions
Pal SK, Bernard-Tessier A, Grell P, Gao X, Kotecha RR, Picus J, de Braud F, Takahashi S, Wong A, Suárez C, Otero JA, Kundamal N, Yang X, Sharaby S, Roy M, Barzaghi-Rinaudo P, Tannir NM. A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma. Clin Cancer Res. 2025 May 15;31(10):1847-1855. doi: 10.1158/1078-0432.CCR-24-2618 This open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2025 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Pal, Sumanta K; Picus, Joel; and et al., "A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma." Clinical Cancer Research. 31, 10. 1847 - 1855. (2025).
https://digitalcommons.wustl.edu/oa_4/5080
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
